Global

PLOS CURRENT OUTBREAKS                                                                              Nov. 21, 2014
By David Fisman and Ashleigh Tuite, Dalla Lana School of Public Health, University of Toronto

As removal of population-level susceptibility through vaccination could be a highly impactful control measure for this epidemic, we sought to estimate the number of vaccine doses and timing of vaccine administration required to reduce the epidemic size. Our base model was fit using the IDEA approach, a single equation model that has been successful to date in describing Ebola growth. We projected the future course of the Ebola epidemic using this model. Vaccination was assumed to reduce the effective reproductive number. We evaluated the potential impact of vaccination on epidemic trajectory under different assumptions around timing of vaccine availability.

INTERNAL DISPLACEMENT MONITORING CENTRE                                                                            Nov.19, 2014

When a whole town was displaced in the south of Guinea during the Ebola crisis, the link between disease and displacement began to emerge. With IDMC monitoring the crisis across the three countries most affected since the outbreak took place, we have identified five key displacement trends emerging.

On 14 November 2014 the UN Mission for Ebola Emergency Response (UNMEER) reported that the Guinean government had announced the withdrawal of troops from Womey, Nzérékoré prefecture, in the south of the country when a group of people raising awareness about the Ebola Virus Disease (EVD) were killed by angry residents.

Since the army’s deployment in September, there have been accusations of human rights violations at the hands of military personnel, resulting in the displacement of the whole town, with some 6,000 residents fleeing to forests in the surrounding area. This is the single largest reported incident of displacement during the Ebola crisis.

                                                                                                    Getty Images

WIRED                 BY Katie M. Palmer                                                    Nov. 24, 214

The FDA announced Friday that it would start developing a stockpile of blood plasma from Ebola survivors, treated with a pathogen inactivation system that’s never been used before in the United States.

So far, the US has had some amazing success in curing Ebola, possibly thanks to experimental plasma treatments. Drawn from survivors, the stuff comes enriched in antibodies that could help to fight off the disease—but it also has the potential to carry other diseases, like malaria, that are common in west Africa where Ebola is raging. The new system will kill off any extra contaminants that may be lurking in this potentially live-saving serum.

It’s the same one, Cerus Corporation’s Intercept system, that will be used in a Gates Foundation-funded study of Ebola treatments in West Africa. The pathogen-killing molecule at the heart of the system is amotosalen, part of a class of three-ringed molecules called psoralens....

Read complete story

USA TODAY                       By Greg Zoraya                                                                                 Nov. 23, 2014

MONROVIA, Liberia — A snapshot of the Ebola epidemic raging across West Africa shows a wildfire of infections only slightly contained.

While cases have been on the decline in Liberia, the outbreak is worsening in neighboring countries, where basic Ebola-fighting tools are impractical.

Identifying the infected and those they've touched, and isolating them to break the transmission chain are all but impossible in Sierra Leone's capital of Freetown as well as the jungles of Guinea, says Jordan Tappero, the Centers for Disease Control and Prevention's second-in-command for the regional response...